Pharmacokinetic Properties of a New Controlled-Release Formulation of Carvedilol

American Journal of Cardiology

Volumn 98, Issue 7 SUPPL., 2006, Pages 5-16

  Tenero, David M ^a   Henderson, Linda S ^a   Baidoo, Charlotte A ^a   Harter, Angela H ^a   Campanile, Andrea M ^a   Danoff, Theodore M ^a   Boyle, Duane ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED DRUG RELEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; ENANTIOMER; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FAILURE; HUMAN; HYPERTENSION; INFUSION PUMP; LIPID DIET; MARKETING; MULTIPLE DRUG DOSE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE; STEREOCHEMISTRY;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; AREA UNDER CURVE; CARBAZOLES; DELAYED-ACTION PREPARATIONS; HUMANS; PROPANOLAMINES;

EID: 33749129554     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.07.014     Document Type: Article

References (14)

1. Coreg (carvedilol) tablets [prescribing information] (2006), GlaxoSmithKline, Research Triangle Park, NC
2. Ruffolo Jr. R.R., Gellai M., Hieble J.P., Willette R.N., and Nichols A.J. The pharmacology of carvedilol. Eur J Clin Pharmacol 38 2 (1990) S82-S88
3. Meier J., Nuesch E., and Schmidt R. Pharmacokinetic criteria for the evaluation of retard formulations. Eur J Clin Pharmacol 7 (1974) 429-432
4. Neugebauer G., Akpan W., Kaufmann B., and Reiff K. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol 38 2 (1990) S108-S111
5. Tenero D., Boike S., Boyle D., Ilson B., Fesniak H.F., Brozena S., and Jorkasky D. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. J Clin Pharmacol 40 (2000) 844-853
6. Henderson L.S., Tenero D.M., Baidoo C.A., Campanile A.M., Harter A.H., Boyle D., and Danoff T.M. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am J Cardiol 98 (2006) 17L-26L
7. Packer M., Lukas M.A., Tenero D.M., Baidoo C.A., Greenberg B.H., and 369 Study Group. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Am J Cardiol 98 suppl (2006) 39L-45L
8. Data on file (2006), GlaxoSmithKline, Research Triangle Park, NC
9. Justesen U.S., and Pedersen C. Diurnal variation of plasma protease inhibitor concentrations. AIDS 16 (2002) 2487-2489
10. Erol K., Kilic F.S., Batu O.S., and Yildirim E. Morning-evening administration time differences in digoxin kinetics in healthy young subjects. Chronobiol Int 18 (2001) 841-849
11. Lemmer B. The importance of circadian rhythms on drug response in hypertension and coronary heart disease-from mice and man. Pharmacol Ther 111 (2006) 629-651
12. Caldwell H.C., Westlake W.J., Schriver R.C., and Bumbier E.E. Steady-state lithium blood level fluctuations in man following administration of a lithium carbonate conventional and controlled-release dosage form. J Clin Pharmacol 21 (1981) 106-109
13. Weber M.A., Sica D.A., Tarka E.A., Iyengar M., Fleck R., and Bakris G.L. Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol 98 (2006) 32L-38L
14. Zhou H.H., and Wood A.J. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 57 (1995) 518-524